Patents by Inventor Kannan Tharakaraman

Kannan Tharakaraman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Bispecific antibodies having constant region mutations and uses therefor
    Patent number: 11459405
    Abstract: Described herein are mutations in the CH1/CL interface and CH3 constant regions of a bispecific antibody which facilitate heterodimerization and methods for the efficient production of bispecific antibodies. Also disclosed are therapeutic and diagnostic methods for using the antibodies.
    Type: Grant
    Filed: December 28, 2016
    Date of Patent: October 4, 2022
    Assignee: Massachusetts Institute of Technology
    Inventors: Ram Sasisekharan, Kannan Tharakaraman, Vidya Subramanian, Eduardo Fleischer, Andrew Peter Hatas
  • Full spectrum anti-dengue antibody
    Patent number: 11421018
    Abstract: The present invention provides, among other things, antibody agents (e.g., antibodies, and/or antigen-binding fragments thereof) that bind to DV epitopes, as well as compositions containing them and methods of designing, providing, formulating, using, identifying and/or characterizing them. In some embodiments, provided antibody agents show significant binding to a plurality of DV serotypes. In some embodiments, provided antibody agents show significant binding to all four DV serotypes. Such antibody agents are useful, for example, in the prophylaxis, treatment, diagnosis, and/or study of DV.
    Type: Grant
    Filed: December 26, 2019
    Date of Patent: August 23, 2022
    Assignee: Massachusetts Institute of Technology
    Inventors: Ram Sasisekharan, Kannan Tharakaraman
  • Antibodies that bind zika virus envelope protein and uses thereof
    Patent number: 11267873
    Abstract: Isolated monoclonal antibodies which bind to Zika virus envelope protein and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: March 8, 2022
    Assignees: Massachusetts Institute of Technology, National University of Singapore
    Inventors: Ram Sasisekharan, Kannan Tharakaraman, Kuan Rong Chan, Satoru Watanabe, Subhash G. Vasudevan, Eng Eong Ooi
  • ANTIBODIES THAT BIND EBOLA GLYCOPROTEIN AND USES THEREOF
    Publication number: 20210095007
    Abstract: Isolated monoclonal antibodies which bind to Ebola virus glycoprotein and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.
    Type: Application
    Filed: December 4, 2020
    Publication date: April 1, 2021
    Inventors: Ram SASISEKHARAN, Kannan THARAKARAMAN, Devin QUINLAN, Vidya SUBRAMANIAN
  • Agents for influenza neutralization
    Patent number: 10947300
    Abstract: The present invention provides antibodies (e.g., monoclonal antibodies, human antibodies, humanized antibodies, etc.), which bind to multiple influenza strains. Such antibodies are useful, for example, in the prophylaxis, treatment, diagnosis, and/or study of influenza.
    Type: Grant
    Filed: November 6, 2019
    Date of Patent: March 16, 2021
    Assignee: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
    Inventors: S. Raguram, Viswanathan Sasisekharan, Venkataramanan Soundararajan, Ram Sasisekharan, Vidya Subramanian, Kannan Tharakaraman
  • Antibodies that bind Ebola glycoprotein and uses thereof
    Patent number: 10894818
    Abstract: Isolated monoclonal antibodies which bind to Ebola virus glycoprotein and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.
    Type: Grant
    Filed: October 2, 2015
    Date of Patent: January 19, 2021
    Assignee: Massachusetts Institute of Technology
    Inventors: Ram Sasisekharan, Kannan Tharakaraman, Devin Quinlan, Vidya Subramanian
  • ANTIBODIES THAT BIND ZIKA VIRUS ENVELOPE PROTEIN AND USES THEREOF
    Publication number: 20210009663
    Abstract: Isolated monoclonal antibodies which bind to Zika virus envelope protein and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.
    Type: Application
    Filed: September 28, 2020
    Publication date: January 14, 2021
    Inventors: Ram SASISEKHARAN, Kannan THARAKARAMAN, Kuan Rong CHAN, Satoru WATANABE, Subhash G. VASUDEVAN, Eng Eong OOI
  • Antibodies that bind Zika virus envelope protein and uses thereof
    Patent number: 10829545
    Abstract: Isolated monoclonal antibodies which bind to Zika virus envelope protein and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: November 10, 2020
    Assignees: Massachusetts Institute of Technology, National University of Singapore
    Inventors: Ram Sasisekharan, Kannan Tharakaraman, Kuan Rong Chan, Satoru Watanabe, Subhash G. Vasudevan, Eng Eong Ooi
  • ANTI-DENGUE VIRUS ANTIBODIES AND USES THEREOF
    Publication number: 20200264176
    Abstract: The present invention provides, among other things, antibody agents (e.g., antibodies, and/or antigen-binding fragments thereof) that bind to DV epitopes, as well as compositions containing them and methods of designing, providing, formulating, using, identifying and/or characterizing them. In some embodiments, provided antibody agents show significant binding to a plurality of DV serotypes. In some embodiments, provided antibody agents show significant binding to all four DV serotypes. Such antibody agents are useful, for example, in the prophylaxis, treatment, diagnosis, and/or study of DV.
    Type: Application
    Filed: February 13, 2020
    Publication date: August 20, 2020
    Inventors: Ram Sasisekharan, Luke Nathaniel Robinson, Kannan Tharakaraman
  • NOVEL FULL SPECTRUM ANTI-DENGUE ANTIBODY
    Publication number: 20200207841
    Abstract: The present invention provides, among other things, antibody agents (e.g., antibodies, and/or antigen-binding fragments thereof) that bind to DV epitopes, as well as compositions containing them and methods of designing, providing, formulating, using, identifying and/or characterizing them. In some embodiments, provided antibody agents show significant binding to a plurality of DV serotypes. In some embodiments, provided antibody agents show significant binding to all four DV serotypes. Such antibody agents are useful, for example, in the prophylaxis, treatment, diagnosis, and/or study of DV.
    Type: Application
    Filed: December 26, 2019
    Publication date: July 2, 2020
    Inventors: Ram Sasisekharan, Kannan Tharakaraman
  • AGENTS FOR INFLUENZA NEUTRALIZATION
    Publication number: 20200123234
    Abstract: The present invention provides antibodies (e.g., monoclonal antibodies, human antibodies, humanized antibodies, etc.), which bind to multiple influenza strains. Such antibodies are useful, for example, in the prophylaxis, treatment, diagnosis, and/or study of influenza.
    Type: Application
    Filed: November 6, 2019
    Publication date: April 23, 2020
    Inventors: S. Raguram, Viswanathan Sasisekharan, Venkataramanan Soundararajan, Ram Sasisekharan, Vidya Subramanian, Kannan Tharakaraman
  • Agents for influenza neutralization
    Patent number: 10538578
    Abstract: The present invention provides antibodies (e.g., monoclonal antibodies, human antibodies, humanized antibodies, etc.), which bind to multiple influenza strains. Such antibodies are useful, for example, in the prophylaxis, treatment, diagnosis, and/or study of influenza.
    Type: Grant
    Filed: April 23, 2018
    Date of Patent: January 21, 2020
    Assignee: Massachusetts Institute of Technology
    Inventors: S. Raguram, Viswanathan Sasisekharan, Venkataramanan Soundararajan, Ram Sasisekharan, Vidya Subramanian, Kannan Tharakaraman
  • Human Adaptation of H7 HA
    Patent number: 10526375
    Abstract: The present invention provides, among other things, systems (e.g., comprising compositions and/or methods) for diagnosis, prophylaxis, treatment, prevention, and/or characterization of influenza transmission and/or infection. The present invention also provides methods for monitoring influenza variants for their potential to present a pandemic risk to humans.
    Type: Grant
    Filed: June 5, 2014
    Date of Patent: January 7, 2020
    Assignee: Massachusetts Institute of Technology
    Inventors: Kannan Tharakaraman, Rahul Raman, Akila Jayaraman, Nathan Wilson Stebbins, Ram Sasisekharan
  • Full spectrum anti-dengue antibody
    Patent number: 10519220
    Abstract: The present invention provides, among other things, antibody agents (e.g., antibodies, and/or antigen-binding fragments thereof) that bind to DV epitopes, as well as compositions containing them and methods of designing, providing, formulating, using, identifying and/or characterizing them. In some embodiments, provided antibody agents show significant binding to a plurality of DV serotypes. In some embodiments, provided antibody agents show significant binding to all four DV serotypes. Such antibody agents are useful, for example, in the prophylaxis, treatment, diagnosis, and/or study of DV.
    Type: Grant
    Filed: January 11, 2018
    Date of Patent: December 31, 2019
    Assignee: Massachusetts Institute of Technology
    Inventors: Ram Sasisekharan, Kannan Tharakaraman
  • ANTIBODIES THAT BIND ZIKA VIRUS ENVELOPE PROTEIN AND USES THEREOF
    Publication number: 20190315838
    Abstract: Isolated monoclonal antibodies which bind to Zika virus envelope protein and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.
    Type: Application
    Filed: October 13, 2017
    Publication date: October 17, 2019
    Inventors: Ram SASISEKHARAN, Kannan THARAKARAMAN, Kuan Rong CHAN, Satoru WATANABE, Subhash G. VASUDEVAN, Eng Eong OOI
  • Human adaptation of H3 influenza
    Patent number: 10301359
    Abstract: The present invention provides, among other things, technologies and methodologies for detection, treatment, and/or prevention of influenza transmission and/or infection. The present invention also provides technologies for monitoring influenza variants for their potential to present a pandemic risk to humans.
    Type: Grant
    Filed: April 30, 2014
    Date of Patent: May 28, 2019
    Assignee: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
    Inventors: Ram Sasisekharan, Kannan Tharakaraman, Rahul Raman
  • HEMAGGLUTININ POLYPEPTIDES, AND REAGENTS AND METHODS RELATING THERETO
    Publication number: 20190142931
    Abstract: The present invention provides a system for analyzing interactions between glycans and interaction partners that bind to them. The present invention also provides HA polypeptides that bind to umbrella-topology glycans, and reagents and methods relating thereto.
    Type: Application
    Filed: January 17, 2019
    Publication date: May 16, 2019
    Inventors: Kannan Tharakaraman, Karthik Viswanathan, Rahul Raman, Ram Sasisekharan
  • Hemagglutinin polypeptides, and reagents and methods relating thereto
    Patent number: 10226527
    Abstract: The present invention provides a system for analyzing interactions between glycans and interaction partners that bind to them. The present invention also provides HA polypeptides that bind to umbrella-topology glycans, and reagents and methods relating thereto.
    Type: Grant
    Filed: October 4, 2011
    Date of Patent: March 12, 2019
    Assignee: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
    Inventors: Kannan Tharakaraman, Karthik Viswanathan, Rahul Raman, Ram Sasisekharan
  • AGENTS FOR INFLUENZA NEUTRALIZATION
    Publication number: 20190062407
    Abstract: The present invention provides antibodies (e.g., monoclonal antibodies, human antibodies, humanized antibodies, etc.), which bind to multiple influenza strains. Such antibodies are useful, for example, in the prophylaxis, treatment, diagnosis, and/or study of influenza.
    Type: Application
    Filed: April 23, 2018
    Publication date: February 28, 2019
    Inventors: S. Raguram, Viswanathan Sasisekharan, Venkataramanan Soundararajan, Ram Sasisekharan, Vidya Subramanian, Kannan Tharakaraman
  • BISPECIFIC ANTIBODIES HAVING CONSTANT REGION MUTATIONS AND USES THEREFOR
    Publication number: 20190023810
    Abstract: Described herein are mutations in the CHl/CL interface and CH3 constant regions of a bispecific antibody which facilitate heterodimerization and methods for the efficient production of bispecific antibodies. Also disclosed are therapeutic and diagnostic methods for using the antibodies.
    Type: Application
    Filed: December 28, 2016
    Publication date: January 24, 2019
    Applicants: Massachusetts Institute of Technology, Massachusetts Institute of Technology
    Inventors: Ram SASISEKHARAN, Kannan THARAKARAMAN, Vidya SUBRAMANIAN, Eduardo FLEISCHER, Andrew Peter HATAS